Kanis, John A. http://orcid.org/0000-0002-3129-4326
Johansson, Helena
Harvey, Nicholas C.
Gudnason, Vilmundur
Sigurdsson, Gunnar
Siggeirsdottir, Kristin
Lorentzon, Mattias
Liu, Enwu
Vandenput, Liesbeth
McCloskey, Eugene V.
Article History
Received: 19 July 2022
Accepted: 2 September 2022
First Online: 26 September 2022
Declarations
:
: The study was approved by the National Bioethics Committee and the Data Protection Authority in Iceland. All participants gave informed written consent.
: V. Gudnason, G. Sigurdsson, K. Siggeirsdottir, E. Liu, L. Vandenput and H. Johansson declare no competing interests.N. Harvey has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma.E. V. McCloskey has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, SanofiAventis, Servier, Synexus, UCB, Viiv, Warner Chilcott, I3 Innovus and Unilever.J. A. Kanis is the architect of FRAX but has no financial interest.M. Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, all outside the presented work.